Marmor et al (p. 439) present updated 2025 recommendations on screening for hydroxychloroquine (HCQ) retinopathy that were approved and ratified at the October 2025 meeting of the AAO Board of Trustees. They report that the retina typically remains clinically normal for many years on HCQ, but signs of toxicity may eventually develop after an unpredictable point in time. The recommended daily dosage remains unchanged at ≤5.0 mg/day/kg real weight. Concurrent renal disease and tamoxifen use and initiation of HCQ therapy at an older age increase the risk of toxicity.